Common Contracts

AGREEMENT AND PLAN OF MERGER by and among: Onconova Therapeutics, Inc., a Delaware corporation; TrawS MERGER SUB I, INC., a Delaware corporation; trawS MERGER SUB II, LLC, a Delaware limited liability company; and Trawsfynydd Therapeutics, Inc., a...

Merger Agreement • April 4th, 2024 • Traws Pharma, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Merger Agreement
• Filed
  April 4th, 2024
• Company
  Traws Pharma, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of April 1, 2024, by and among ONCONOVA THERAPEUTICS, INC., a Delaware corporation (“Parent”), TRAWS MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), TRAWS MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and TRAWSFYNYDD THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER by and among: AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation; ASPEN MERGER SUB I, INC., a Delaware corporation; SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company; and SPYRE THERAPEUTICS, INC., a...

Merger Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Merger Agreement
• Filed
  December 22nd, 2023
• Company
  Spyre Therapeutics, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of June 22, 2023, by and among AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation (“Parent”), ASPEN MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and SPYRE THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER by and among: AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation; ASPEN MERGER SUB I, INC., a Delaware corporation; SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company; and SPYRE THERAPEUTICS, INC., a...

Merger Agreement • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Merger Agreement
• Filed
  November 15th, 2023
• Company
  Aeglea BioTherapeutics, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of June 22, 2023, by and among AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation (“Parent”), ASPEN MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and SPYRE THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER by and among

Merger Agreement • November 13th, 2023 • Selecta Biosciences Inc • Pharmaceutical preparations • Delaware

• Contract Type
  Merger Agreement
• Filed
  November 13th, 2023
• Company
  Selecta Biosciences Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of November 13, 2023, by and among SELECTA BIOSCIENCES, INC., a Delaware corporation (“Parent”), SAKURA MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), SAKURA MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and, together with First Merger Sub, “Merger Subs”), and CARTESIAN THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER among: BAUDAX BIO, INC., BOUNCE MERGER SUB I, INC., BOUNCE MERGER SUB II, LLC, and TERAIMMUNE, INC. Dated as of June 29, 2023

Merger Agreement • July 5th, 2023 • Baudax Bio, Inc. • Services-misc health & allied services, nec • Delaware

• Contract Type
  Merger Agreement
• Filed
  July 5th, 2023
• Company
  Baudax Bio, Inc.
• Industry
  Services-misc health & allied services, nec
• Jurisdiction
  Delaware

This AGREEMENT AND PLAN OF MERGER is made and entered into as of June 29, 2023, by and among Baudax Bio, Inc., a Pennsylvania corporation (“Parent”), Bounce Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), Bounce Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and, together with First Merger Sub, “Merger Subs”), and TeraImmune, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER by and among: AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation; ASPEN MERGER SUB I, INC., a Delaware corporation; SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company; and SPYRE THERAPEUTICS, INC., a...

Merger Agreement • June 23rd, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Merger Agreement
• Filed
  June 23rd, 2023
• Company
  Aeglea BioTherapeutics, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of June 22, 2023, by and among AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation (“Parent”), ASPEN MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and SPYRE THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER among: IDERA PHARMACEUTICALS, INC., a Delaware corporation; BELL MERGER SUB I, INC., a Delaware corporation; BELL MERGER SUB II, LLC, a Delaware limited liability company; and ACERAGEN, INC., a Delaware corporation Dated...

Merger Agreement • September 30th, 2022 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware

• Contract Type
  Merger Agreement
• Filed
  September 30th, 2022
• Company
  Idera Pharmaceuticals, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Delaware

This AGREEMENT AND PLAN OF MERGER is made and entered into as of September 28, 2022, by and among IDERA PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), BELL MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), BELL MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and, together with First Merger Sub, “Merger Subs”), and ACERAGEN, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER among: APREA THERAPEUTICS, INC., a Delaware corporation; ATR MERGER SUB I INC., a Delaware corporation; ATR MERGER SUB II LLC, a Delaware limited liability company; and ATRIN PHARMACEUTICALS INC., a Delaware corporation...

Merger Agreement • May 17th, 2022 • Aprea Therapeutics, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Merger Agreement
• Filed
  May 17th, 2022
• Company
  Aprea Therapeutics, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of May 16, 2022, by and among Aprea Therapeutics, Inc., a Delaware corporation (“Parent”), ATR Merger Sub I Inc., a Delaware corporation and wholly owned Subsidiary of Parent (“First Merger Sub”), ATR Merger Sub II LLC, a Delaware limited liability company and wholly owned Subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and Atrin Pharmaceuticals Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER among: MIRAGEN THERAPEUTICS, INC., a Delaware corporation; OCULUS MERGER SUB I, INC., a Delaware corporation; OCULUS MERGER SUB II, LLC, a Delaware limited liability company; and VIRIDIAN THERAPEUTICS, INC., a Delaware...

Merger Agreement • October 28th, 2020 • Miragen Therapeutics, Inc. • Services-medical laboratories • Delaware

• Contract Type
  Merger Agreement
• Filed
  October 28th, 2020
• Company
  Miragen Therapeutics, Inc.
• Industry
  Services-medical laboratories
• Jurisdiction
  Delaware

THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of October 27, 2020, by and among MIRAGEN THERAPEUTICS, INC., a Delaware corporation (“Parent”), OCULUS MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), OCULUS MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and VIRIDIAN THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.